Focusing on improvements in metabolism and body weight and the recovery of leptin sensitivity obtained from in vivo blunted deletion of leptin [111], Zhao et al. investigated a novel anti-obesity strategy consisting of treatment with human anti-leptin antibodies (hLep2, hLep3, hLep5). The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.